Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec + liraglutide vs insulin glargine in obese type 2 diabetes with poor glycemic control
ChiCTR2500105275Phase 4Not yet recruiting
- Sponsor
- Jiangjin Central Hospital
- Start
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of insulin degludec, liraglutide and insulin glargine in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Jiangjin Central Hospital. Primary endpoint: Glycated hemoglobin (HbA1c). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2500105275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105275.